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ABSTRACT
Kaposi’s sarcoma (KS)-associated herpesvirus (KSHV) is a human gammaherpesvirus associated with several human ma-
lignancies. The replication and transcription activator (RTA) is necessary and sufficient for the switch from KSHV latency
to lytic replication. Interleukin 1 (IL-1) is a major mediator for inflammation and plays an important role in both innate
and adaptive immunity. Myeloid differentiation primary response gene 88 (MyD88) is an essential adaptor molecule for
IL-1 as well as most Toll-like receptor signaling. In this study, we identified a novel mechanism by which KSHV interferes
with host inflammation and immunity. KSHV RTA specifically reduces the steady-state protein levels of MyD88, and phys-
iological levels of MyD88 are downregulated during KSHV lytic replication when RTA is expressed. The N-terminal region
of RTA is required for the reduction of MyD88. Additional studies demonstrated that RTA targets MyD88 expression at the
RNA level, inhibits RNA synthesis of MyD88, and may bind MyD88 RNA. Finally, RTA inhibits IL-1-mediated activation of
NF-B. Because IL-1 is abundant in the KS microenvironment and inhibits KSHV replication, this work may expand our
understanding of how KSHV evades host inflammation and immunity for its survival in vivo.
IMPORTANCE
MyD88 is an important molecule for IL-1-mediated inflammation and Toll-like receptor (TLR) signaling. This work shows that
KSHV inhibits MyD88 expression through a novel mechanism. KSHV RTA may bind to MyD88 RNA, suppresses RNA synthesis
of MyD88, and inhibits IL-1-mediated signaling. This work may expand our understanding of how KSHV evades host inflamma-
tion and immunity.
Kaposi’s sarcoma (KS)-associated herpesvirus (KSHV), alsoknown as human herpesvirus 8 (HHV-8), is a gammaherpes-
virus. It is believed to be the etiological agent of KS (1–3). In
addition, KSHV is implicated in the pathogenesis of AIDS-associ-
ated primary effusion lymphoma (PEL, also called body cavity-
based lymphoma [BCBL]) and a lymphoproliferative disorder
known as multicentric Castleman’s disease (3–5).
Like other herpesviruses, KSHV goes through both latency and
lytic replication cycles. The expression of the KSHV replication
and transcription activator (RTA) is necessary and sufficient for
the switch from latency to lytic replication (4, 5). RTA is an im-
mediate early gene (6–8) and a sequence-specific DNA-binding
protein (7–13). RTA also interacts with other factors, such as cel-
lular recombination signal sequence-binding protein J (RBP-J)
(also known as CBF-1 and CSL), to modulate its transcription
potential (14–16). Other than transcriptional regulation, RTA
modulates protein degradation. RTA was first documented as a
ubiquitin E3 ligase for degradation of cellular interferon regula-
tory factor 7 (IRF-7) (17). Many more proteins, including TIR
domain-containing adapter-inducing interferon beta (TRIF) and
KSHV-RTA binding protein (K-RBP), have been identified as tar-
gets by RTA for degradation with the same pathway (18–21).
The host inflammation and immune responses are essential for
the initial detection of invading viruses and subsequent antago-
nizing invaders. The interleukin 1 (IL-1) family is a group of 11
cytokines which play a central role in the regulation of immune
and inflammatory responses to infections. They act on innate im-
mune cells to influence their survival and function. In addition,
they act directly on lymphocytes to reinforce certain adaptive im-
mune responses (for a review, see reference 22). Myeloid differen-
tiation primary response gene 88 (MyD88) is an adaptor molecule
that plays an essential role in mediation of IL-1 signaling. In ad-
dition, MyD88 is a critical adaptor for all Toll-like receptor (TLR)
signaling pathways, except that of TLR3, to activate NF-B (23–
25). TLRs are able to recognize molecular patterns unique to
pathogens and activate host innate immunity against the patho-
gen (26, 27).
KSHV needs to counteract host inflammation and innate-im-
munity-mediated antiviral responses. KSHV has abundant IL-1 in
its microenvironment, and IL-1 inhibits its replication (28–31).
KSHV uses microRNAs (miR-K9 and miR-K5) to target the IL-1
downstream components IRAK1 and MyD88 (32). TLR4 has been
identified as an important molecule against KSHV infection, and
KSHV has developed a mechanism for rapid suppression of TLR-4
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expression (33). Also, murine gammaherpesvirus 68 (MHV68) is
another herpesvirus with significant similarities to KSHV. Activa-
tion of the TLR3/TLR4 pathway potently inhibits the replication
of MHV68 in vivo (34). Thus, a successful counteraction of host
inflammation and immunity may be a necessity for the survival of
KSHV in vivo.
Previously, we have found that RTA degrades TRIF and blocks
TLR3-mediated antiviral responses (18). In this study, we found
that RTA also downregulates expression of MyD88 to block the
host inflammation and innate immunity. Interestingly, the reduc-
tion of MyD88 was at the RNA level rather than by protein degra-
dation. RTA may be a RNA-binding protein that targets MyD88
RNA and consequently inhibits its synthesis. This report describes
another mechanism by which KSHV counteracts host defense sys-
tems following infection.
MATERIALS AND METHODS
Plasmids, antibodies, and drugs. Expression plasmids of KSHV RTA and
its mutants (RTA-K152E, RTA-C, RTA-N, RTA-H145L, and RTA-
C141S), Epstein-Barr virus (EBV) RTA, MyD88, and TRAM were de-
scribed previously (35–39). Mutagenesis to generate MyD88 mutants
(MyD88-N and MyD88-C) was done by the use of PCR and cloned into a
3-FLAG vector (Sigma). The expression clones were all sequenced to ver-
ify their validity. RTA antibody was described previously (40). Tubulin
(T6557) and FLAG (F1804) antibodies were obtained from Sigma. The
antibodies for GAPDH (sc-47724), MyD88 (sc-11356), MDM2 (sc-965),
and IRF-1 (sc-497) were from Santa Cruz. TRIF antibody was from Cell
Signaling (catalog number 4596). The proteasome inhibitor lactacystin
was purchased from Assay Designs and used at 1 to 10M. For lactacystin
treatment, cells were transfected, and medium was removed 4 to 6 h after
transfection. Fresh medium plus the appropriate concentrations of drugs
were added. Cells were collected 12 to 24 h later.
Cell culture and transient transfection. 293T is a human fibroblast
line, and 293T cells were grown in Dulbecco’s modified Eagle medium
(DMEM; Gibco BRL) supplemented with 10% fetal bovine serum (FBS;
Gibco BRL) and 1% penicillin-streptomycin (PS) at 37°C with 5% CO2
incubation. P3HR1 is a KSHV-negative but EBV-positive Burkitt’s lym-
phoma cell line. BCBL1 is a KSHV-positive, EBV-negative primary effu-
sion lymphoma line. These cells were maintained in RPMI 1640 plus 10%
FBS.
Transient transfection, cytokines, and reporter assays. The transfec-
tion reagent Attractene (Qiagen catalog no. 301007) was used for the
transfection of 293T cells following the manufacturer’s recommenda-
tions. Interleukin 1 (IL-1; catalog no. 201-LB) and tumor necrosis
factor alpha (TNF-; catalog no. 210-TA) were purchased from R&D
Systems. Luciferase assays were performed using the luciferase assay kit
(catalog no. E1501) from Promega according to the manufacturer’s rec-
ommendation. -Galactosidase assays were also performed for transfec-
tion efficiency. Data were averaged from triplicate experiments.
Protein and RNA stability assays. The protein biosynthesis inhibitor
cycloheximide (Sigma catalog no. C4859) was used at 50 to 100 g/ml.
Cells were transfected in 10-cm dishes, and transfected cells were split 4 to
6 h after transfection into 6-well plates. Next day, the cells were treated
with cycloheximide for various periods, and cell lysates were used for
Western blot analysis. For RNA stability, the RNA synthesis inhibitor
actinomycin D (Sigma catalog no. A1410) was used at 10 g/ml. Trans-
fected cells were split 4 to 6 h after transfection into 6-cm dishes. The next
day, the cells were treated with actinomycin D for various periods and
collected for total-RNA isolation.
Western blot analysis, RNA extraction, and reverse transcription-
PCR (RT-PCR) analysis. Standard Western blot analysis was performed
as described previously (41–43). Total RNA was isolated from cells using
TRIzol extraction. cDNA was synthesized with SuperScript reverse trans-
criptase (Invitrogen catalog no. 18064-014) and random hexamers (Invit-
rogen catalog no. 48190-011). The primers used for PCR analysis are listed
in Table 1. The signal strengths were enumerated by the use of the Bio-Rad
software Quantity One (version 4.6.7).
Isolation of newly transcribed RNA. Newly transcribed RNA was iso-
lated using the Click-iT nascent-RNA capture kit from Life Technology
(catalog no. C10365). This method enables the metabolic incorporation
of ethynyl uridine (EU)—a “clickable” ribonucleotide— onto RNA dur-
ing nascent-RNA synthesis. Biotin is then “clicked” onto the nascent
chain, and streptavidin magnetic beads are used to capture the nascent
RNA. The cells were labeled with EU (200 mM) for 30 to 60 min. The
newly synthesized RNA (with EU incorporation) was isolated from total
RNA by following the manufacturer’s recommendations. The cDNA was
synthesized with a SuperScript VILO cDNA synthesis kit (Life Technology
catalog no. 11754-050) as recommended by the manufacturer.
RNA-ChIP assay. RNA-chromatin immunoprecipitation (RNA-
ChIP) essentially followed the published protocol (44) and the corre-
sponding online protocol [“RNA-chromatin immunoprecipitations
(RNA-ChIP) in mammalian cells (PROT28)” (http://www.protocol
-online.org/cgi-bin/prot/view_cache.cgi?ID3241)]. Briefly, cells were
grown in a 10-cm culture dish and transfected with plasmids. One day
later, cells were cross-linked with formaldehyde for 30 min at room tem-
perature. Glycine was added, and the cells were washed twice with ice-cold
PBS containing 1 protease inhibitor cocktail (Roche catalog no. 05892).
Cell lysates were sonicated two or three times for 30 s each (Virtis Virsonic
cell disruptor; power level 3). Sonicates were diluted, and an aliquot was
TABLE 1 Primer sequences used for RT-PCR analysis in this studya
Name Sequence (5=¡3=) Purpose or region
LGH4930 TTCGCCTGTTAGACGAAGC KSHV RTA detection
LGH4929 GATTCGCAAGCTTCAGTCTCGGAAGTAATTACG
Actin1 TTCTACAATGAGCTGCGTGT Actin detection
Actin2 GCCAGACAGCACTGTGTTGG
MyD88AF CGGAATTCAATGGCTGCAGGAGGTCCCGGCGCGGGG Region A: aa 1–75
MyD88AR GGGGATCCCTTACAGCAGCCTGCCAGTGGGGTCCGCTTGT
MyD88BF CGGAATTCAGACGCCTGGCAGGGACGCCCT Region B: aa 76–151
MyD88BR GGGGATCCCTTAATCAAGTGTGGTGATGCCCGCCAGCTC
MyD88CF CGGAATTCAGACCCCCTGGGGCATATGCCTGAG Region C: aa 152–225
MyD88CR GGGGATCCCTTAATCAGAGACAACCACCACCATCC
MyD88DF CGGAATTCAGATTACCTGCAGAGCAAGGAA Region D: aa 226–296
MyD88DR GGGGATCCCTCAGGGCAGGGACAAGGCCTTGGCAAG
TRIF1 GCCACGTCCCGCAGCGAGGCGGGGCAC TRIF detection
TRIF2 CGGAATTCAATGGCCTGCACAGGCCCATCAC
a For MyD88 primers, the amino acid (aa) coordinates of the regions covered are provided.
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preserved as an input sample and frozen at	80°C until the reverse cross-
linking step. Normal rabbit serum (NRS) or RTA antibodies and Protein
A/G Plus agarose (Santa Cruz catalog no. 2003) were added to cell lysates,
and the mixture rotated slowly at 4°C overnight. Immune complexes were
collected, eluted, and placed at 65°C for 2 h to reverse the cross-linking.
Proteinase K (Ambion catalog no. 25530-049) was added and incubated at
42°C for 45 min. Samples were subjected to phenol extraction and ethanol
precipitation with Glycoblue (Ambion catalog no. AM9515) as a carrier.
DNA from the samples was removed by the use of DNase I (Ambion
catalog no. AM1907). Sometimes DNase treatment was repeated one
more time. Routine RT-PCR was carried out.
RESULTS
RTA reduces steady-state protein levels of MyD88. Previously,
we found that RTA degrades TRIF protein (18). To assay for other
TLR signaling molecules, we examined several other molecules
involved in TLR signaling. 293T cells were cotransfected with tar-
get gene and RTA expression plasmids, and 1 day later, cell lysates
were used to examine target gene expression. As shown in Fig. 1,
we found that MyD88 protein levels were reduced in the presence
of RTA. EBV RTA (E-RTA) and KSHV RTA have significant ho-
mologies, and both viruses are gammaherpesviruses. However,
KSHV RTA-mediated reduction seems to be specific, as E-RTA
was unable to reduce the expression of MyD88 (Fig. 1A). Other
molecules, such as TRAM, were not affected in the presence of
KSHV RTA (data not shown). Thus, the data suggest that RTA
reduced MyD88 protein expression specifically.
The expression of RTA and that of MyD88 are inversely cor-
related in virus-infected cells. To examine whether RTA could
affect MyD88 protein expression under physiological conditions,
lytic replication of KSHV was induced in latently infected BCBL
cells with chemicals. RTA is not expressed during the viral latency,
but it is a key mediator for the switch from latency to lytic repli-
cation. When KSHV-positive BCBL1 cells were treated with so-
dium butyrate, RTA expression was significantly increased (Fig.
1B). In addition, a simultaneous downregulation of endogenous
MyD88 protein expression occurred. Furthermore, we tested if
MyD88 was degraded in KSHV-negative cell lines. P3HR1 is an
EBV-positive but KSHV-negative Burkitt’s lymphoma cell line.
With the sodium butyrate treatment, MyD88 steady-state levels
did not change noticeably (Fig. 1B). These results suggest that the
reduction of MyD88 was specifically associated with the induction
of RTA under physiological conditions.
The N-terminal region of RTA is required for the modulation
of MyD88. It is well known that RTA could serve as a ubiquitin
ligase and degrade a protein through the proteasome pathway. To
test whether the proteasome pathway was involved in reducing
MyD88 levels, three RTA mutants defective in initiating the pro-
teasome pathway were examined (Fig. 2A). Those mutant plas-
mids were transfected into cells along with the MyD88 expression
plasmid. The expression of MyD88 was examined 1 day later.
While RTA-H145L had a limited effect on MyD88 expression,
RTA-K152E and RTA-C141S both reduced MyD88 expression
significantly (Fig. 2B). In addition, RTAN, but not RTAC, was
unable to decrease MyD88 expression effectively. Interestingly,
the two mutants have very different molecular weights, and this
may need further investigation. Those data suggest that the N
terminus of RTA is involved in the modulation of MyD88 expres-
sion. The proteasome pathway may be partially employed, as the
residue His-145 of RTA is involved in MyD88 regulation. In ad-
dition, a novel mechanism of MyD88 reduction is apparently
present.
To localize the sequences of MyD88 that are important for
RTA-mediated reduction, two mutants were made (Fig. 2C). As
shown in Fig. 2D, the N terminus of MyD88 is the main region
responsive to RTA, and the C terminus is still responsive but less
efficient. The data suggest that RTA targets MyD88 expression
through multiple regions.
RTA does not directly affect MyD88 protein stability. To
study further if the proteasome pathway was involved in MyD88
protein reduction, we studied MyD88 protein stability in the pres-
ence of RTA. 293T cells were transfected with MyD88, with or
without an RTA expression plasmid. One day later, cells were
treated with cycloheximide to block de novo protein synthesis. Cell
lysates were made at various time points after cycloheximide treat-
ment. As shown in Fig. 3A, while MyD88 protein was reduced in
the presence of RTA, the stability of MyD88 protein was not no-
ticeably changed in the presence or absence of RTA. RTA protein
stabilities were also similar with and without MyD88. The half-life
of IRF-1 protein was short, as expected (Fig. 3B) (45), suggesting
that the protein degradation pathway was functional. These re-
sults suggest that protein stability might not be a major mecha-
nism by which RTA regulates MyD88 levels.
RTA modulates MyD88 at RNA levels. Additional studies
were performed to determine whether RTA regulated MyD88 at
the RNA level. Cells were transfected with RTA and MyD88 ex-
pression plasmids with various combinations. RNA were isolated,
and semiquantitative RT-PCR was used for determining the levels
of MyD88 RNA. As shown in Fig. 4A, MyD88 RNA was degraded
in the presence of RTA. Whether endogenous MyD88 RNA was
affected by RTA was examined as well. As shown in Fig. 4B, en-
dogenous MyD88 RNA levels in 293T cells were reduced when
RTA was expressed. Moreover, whether endogenous RTA could
inhibit endogenous MyD88 RNA under physiological conditions
was examined. As described above, the lytic replication of KSHV
was induced, and the increase of RTA was observed (Fig. 1B). RNA
were isolated and processed for RT-PCR. As shown in Fig. 4C,
reduced levels of endogenous MyB88 RNA was observed in KSHV
lytic replications. Therefore, physiological levels of RTA were in-
FIG 1 RTA modulates the expression of MyD88 protein. (A) RTA reduces the
expression of MyD88 protein. 293T cells were transfected with cDNA3, RTA,
EBV-RTA (EBV-R) (0.2 g), and the MyD88 expression plasmid (0.1 g) in
various combinations, as shown on the top. E-RTA has significant homologies
with KSHV RTA. Total DNA for transfection was kept the same with the use of
vector DNA. The cell lysates were obtained 1 day later for Western blot anal-
ysis. The membrane was stripped and probed with another antibody. Images in
the same box are derived from the same membranes. (B) MyD88 is downregu-
lated during KSHV lytic replication. BCBL1 (KSHV
) and P3HR1 (KSHV	)
cells were treated with sodium butyrate for 24 h. Cell lysates were made, and
the expression of endogenous proteins was analyzed by Western blotting. The
membrane was stripped and probed with another antibody. The same cell
lysates were used, and images in the same box are derived from the same
membranes.
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versely correlated with MyD88 RNA expression following KSHV
lytic replication.
Because RTA activates the proteasome pathway, we examined
if RTA-mediated downregulation of MyD88 was affected by a pro-
teasome inhibitor. MyD88 expression was analyzed in the pres-
ence of lactacystin, a potent inhibitor of the 26S proteasome. Lac-
tacystin could not block the downregulation of MyD88 at both
protein and RNA levels (Fig. 4D and E). The effectiveness of lac-
tacystin was confirmed by MDM2 expression (Fig. 4E) (46, 47). In
addition, we transfected TRIF, MyD88, and RTA together into
cells. While both TRIF and MyD88 protein levels were reduced as
expected, the level of MyD88 RNA, but not TRIF RNA, was re-
duced (data not shown) (18). These data suggested that RTA tar-
geted MyD88 predominantly at the RNA level in transfection
studies.
RTA decreases the MyD88 RNA synthesis rate. Once it was
established that RTA inhibited MyD88 at the RNA level, we ad-
dressed whether RTA targeted MyD88 RNA synthesis and/or deg-
radation. Ethynyl uridine (EU) is a special nucleotide that can
specifically replace uridine and can be synthesized onto RNA dur-
ing nascent-RNA synthesis. The newly synthesized RNA with EU
can be isolated specifically from total RNA (see Materials and
Methods for details). The relative rates of RNA synthesis could be
calculated and compared. The transfected cells were labeled with
EU for a short period of time, and de novo synthesized RNAs were
isolated. The relative rates of MyD88 RNA synthesis were calcu-
lated. As shown in Fig. 5A and B, the rate of synthesis of new
MyD88 RNA was lower in RTA- and MyD88-cotransfected cells
than in cells transfected with MyD88 only.
Next, the degradation of MyD88 RNA in the presence of RTA
was examined. Actinomycin D was used to block de novo RNA
synthesis, and RNAs were isolated at various times. Relative
MyD88 RNA stability was measured using actin RNA as a stan-
dard. As shown in Fig. 5C, MyD88 RNA stability was not changed
drastically in the presence or absence of RTA. Because actin RNA
was also degraded accordingly, the relative amounts of MyD88
RNA (MyD88 RNA/actin RNA) did not show a linear reduction
(Fig. 5C). Those studies revealed that RTA inhibited primarily the
synthesis, not the degradation, of MyD88 RNA.
RTA may bind to MyD88 RNA. Because RTA modulates
MyD88 expression in both ectopic (driven by the cytomegalovirus
[CMV] promoter/enhancer) and endogenous (driven by the na-
tive MyD88 promoter/enhancer) settings (Fig. 1 to 4), and RTA-
K152E, a DNA binding mutant (38), regulates MyD88 expression
FIG 2 Domain analysis of RTA for MyD88 reduction. (A) Schematic diagram of RTA mutant constructs. The numbers denote the amino acid positions. The
drawing is not to scale. (B) The N terminus of RTA is required for MyD88 regulation. 293T cells were transfected with vector pcDNA3 and with MyD88 (0.1g),
RTA (0.2 g), and RTA mutant expression plasmids (0.2 g) in various combinations, as shown at the top. The amount of total DNA for transfection was kept
the same with the use of vector DNA. Cell lysates were made 1 day later, and Western blot analysis was performed with RTA, FLAG, and tubulin antibodies. (C)
Schematic diagram of MyD88 mutant constructs. The numbers denote amino acid positions of MyD88. The drawing is not to scale. (D) Multiple regions of
MyD88 are targeted by RTA. 293T cells were transfected with vector pcDNA3 and with MyD88 (0.1 g), RTA (0.2 g), or MyD88 deletion mutant plasmids in
various combinations, as shown at the top. The amount of total DNA for transfection was kept the same with the use of vector DNA. Cell lysates were made 1 day
later, and Western blot analysis was performed with FLAG and GAPDH antibodies.
FIG 3 RTA did not affect the MyD88 protein stability. (A) MyD88 is a rela-
tively stable protein. 293T cells in a 10-cm dish were transfected with MyD88
(0.4g) RTA, or MyD88 plus RTA (0.8g) expression plasmids. The amount
of total DNA for transfection was kept the same with the use of vector DNA. At
6 h after transfection, cells were split into a 6-well plate. Cycloheximide (100
g/ml) was added after a 12-h incubation. Cell lysates were made at various
times, as shown on the top, and Western blot analysis was performed. The
membrane was stripped and probed with another antibody. Images in the
same box are derived from the same membranes. (B) Detection of IRF1 sta-
bility. The lysates used for panel A were used. IRF1 protein stability was mea-
sured in MyD88 and MyD88 plus RTA-transected cells.
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(Fig. 2), we suspected that RTA might regulate MyD88 RNA syn-
thesis through RNA binding. Whether RTA could bind to MyD88
RNA was examined by RNA-ChIP assay. Because there was no
apparent target region(s) for RTA binding, we tested RNA binding
activity covering the entire MyD88 coding sequences in four dif-
ferent regions (Fig. 6A; Table 1). In five independent experiments,
while region B was consistently detected by RNA-ChIP, region A
was difficult to detect. Regions C and D were not consistently
detected. The authenticity of RNA-derived fragments was estab-
lished (Fig. 6C). These experiments suggested that RTA may bind
to region B of MyD88 RNA but not to region A. At the same time,
RTA might bind to regions C and D weakly.
RTA downregulates the IL-1 signaling pathway. MyD88 is an
essential component for IL-1 signaling as well as signaling path-
ways for several TLRs, such as TLR7 and TLR9. Due to the abun-
dance of IL-1 in KS lesions, we tested if RTA blocked IL-1-medi-
ated signaling pathway by assaying NF-B activation. 293T cells
were transfected with RTA and an NF-B reporter construct, and
transfected cells were treated with IL-1. As shown in Fig. 7A, the
NF-B reporter was activated in response to IL-1. However, in
the presence of RTA, the activation was drastically reduced. We
also tested if RTA blocked NF-B activation induced by TNF-:
RTA did not inhibit TNF--mediated NF-B activation (data not
shown), in agreement with a previous report (19). Of note, TNF-
activates NF-B through a different pathway, and MyD88 is not
involved (48). In addition, RTAC, but not RTAN, could in-
hibit IL-1-mediated activation of NF-B (Fig. 7B). Finally, RTA,
but not RTAN, directly inhibited MyD88-mediated activation of
NF-B (Fig. 7C). Those data showed a clear correlation between
blockages of NF-B activation and RTA’s ability to downregulate
MyD88 (Fig. 2). Collectively, these data suggest that RTA blocks
the IL-1 signaling pathway, possibly through MyD88.
DISCUSSION
KSHV needs to counteract host immune responses for a successful
infection in vivo, and it has developed many mechanisms for the
evasion of host innate immunity (17, 18, 33, 49–51). In this report,
we have found that RTA may target MyD88 for inhibition of IL-
1-mediated inflammation. First, we found that RTA reduces ex-
pression of MyD88 at both protein and RNA levels (Fig. 1A, 3, and
FIG 4 RTA reduces MyD88 RNA expression. (A) RTA reduces the RNA expression of MyD88 in transfected cells. 293T cells were transfected with a MyD88 or
MyD88-plus-RTA expression plasmid. The amount of total DNA for transfection was kept the same with the use of vector DNA. Cell were collected 24 h after
transfections, and RNA was isolated. Semiquantitative RT-PCR was carried out with specific primers. (B) RTA reduces endogenous MyD88 RNA expression.
293T cells were transfected with RTA and MyD88 expression plasmids. Total RNA were isolated 24 h after transfections. Semiquantitative RT-PCR was carried
out with specific primers. Primers MyD88AF and MyD88BR for MyD88 were used for panels A and B. (C) MyD88 RNA is downregulated during KSHV lytic
replication. BCBL1 (KSHV
) cells were treated with sodium butyrate for 24 h. Total RNAs were isolated 24 h after treatments. Semiquantitative RT-PCR was
carried out with specific primers at the same time. (D) Lactacystin did not modulate the expression of MyD88 RNA. 293T cells were transfected with various
expression plasmids. At 4 to 6 h after transfection, cells were treated with lactacystin (10 M). On the next day, total RNAs were isolated, and semiquantitative
RT-PCR was carried out with specific primers. Primer MyD88BF and MyD88BR were used for panels C and D. (E) Lactacystin did not modulate the expression
of MyD88 protein. Cell lysates were obtained from the experiment whose results are shown in panel D, and MyD88, tubulin, and MDM2 expression was
examined by Western blotting.
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4). Second, the regulation of MyD88 is apparently present under
physiological conditions, as induction of lytic replication, and
thus the RTA expression, reduces the expression of endogenous
MyD88 at both protein and RNA levels (Fig. 1 and 4).
This RTA-mediated reduction of MyD88 RNA apparently oc-
curs through a novel mechanism. We have found that the rate of
MyD88 RNA synthesis is reduced in the presence of RTA (Fig. 5A
and B), and MyD88 RNA stability is not obviously influenced by
RTA in the same system (Fig. 5C). Furthermore, RTA may bind to
MyD88 RNA, especially to region B (Fig. 6 and Table 1). Based on
all the data presented in this study, we propose the following
mechanism by which KSHV modulates MyD88 expression. KSHV
infection leads to RTA expression. RTA binds to newly synthe-
sized MyD88 RNA, reduces its elongation function, and inhibits
the rate of MyD88 RNA synthesis. The result is the reduction of
MyD88 expression. Of note, due to the limitations of the RNA-
ChIP assay, we cannot rule out the possibility that RTA may bind
to MyD88 RNA indirectly through another molecule(s). In addi-
tion, RTA may still bind to MyD88 DNA directly or indirectly and
modulate its transcription.
It is interesting that KSHV RTA could degrade MyD88 but not
its EBV counterpart, EBV-R (Fig. 1). Both EBV and KSHV are
FIG 5 RTA reduces the rate of MyD88 RNA synthesis. (A) RTA reduces the relative RNA synthesis rate for MyD88. 293T cells were transfected with various
plasmids, as shown at the top. The cells were labeled with ethynyl uridine (EU) for 30 to 60 min, and total RNAs were isolated. The EU-containing RNA (newly
synthesized) was isolated from the total RNA with the use of a Click-iT nascent-RNA capture kit as described in Materials and Methods. RT-PCR were carried
out with the appropriate primers. The PCR products were separated in a polyacrylamide gel. The relative MyD88 RNA levels were determined (MyD88
RNA/actin RNA). The relative new synthesis rate was calculated as relative newly synthesized MyD88 RNA (EU-labeled MyD88/EU-actin) versus relative total
MyD88 RNA (total MyD88/total actin). (B) Comparison of relative MyD88 synthesis rates. The average relative synthesis rates with and without RTA from five
independent experiments are shown. Statistical calculation was done with Microsoft Excel. **, P 0.01. (C) MyD88 RNA stability is not affected drastically by
RTA. RTA and MyD88 plasmids were transfected into 293T cells. More MyD88 plasmid was transfected in the presence of RTA (shown at the top) in order to
achieve similar MyD88 RNA levels. One day after transfection, the cells were labeled with actinomycin D to inhibit RNA synthesis. Total RNAs were isolated at
the various times (hours posttreatment), and MyD88 RNA levels were detected by semiquantitative RT-PCR. Actin levels were used as a control. Results of one
representative experment of three independent experiments are shown.
FIG6 RTA may bind to MyD88 RNA. (A) Schematic diagram of primers used for detection of MyD88 RNA. The four pairs of primers are used to detect different
regions of MyD88 RNA (Table 1). All four products are approximately the same length, around 230 bp. The drawing is not to scale. (B) RTA may bind to MyD88
RNA. 293T cells were transfected with expression plasmids as shown on the top. One day after transfection, cells were fixed with formaldehyde for 30 min and
sonicated briefly to avoid extensive damage to RNA. Normal rabbit serum (NRS) and RTA antibody were used for the RNA-ChIP assay. After digestion with
DNase, RT-PCR was carried out with the appropriate primers, shown in panel A. Results from four independent experiments are shown. (C) RTA may selectively
bind to MyD88 RNA. RNA-ChIP were done as above, and primer pairs A and B were used for detection. Input RNA (1:100) was used as a control. Results of one
representative experiment are shown.
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gammaherpesviruses, and they encode RTAs with significant ho-
mologies. However, they have slight differences in cell tropism,
and the roles of the two RTAs seem to be different in different
viruses. In EBV, BZLF1 is a major player in inducing EBV lytic
replication, and EBV-R is a minor player. In contrast, KSHV RTA
is the major player and critical for KSHV lytic replication, and it
has several mechanisms to block the host’s innate immunity. The
differences in their ability to regulate MyD88 may represent their
general roles in different viruses.
The ability of KSHV RTA to bind to RNA is novel. Some her-
pesvirus proteins can bind to RNA. EBV EBNA1 has been shown
to be an RNA-binding protein that plays a role in viral genome
replication (52, 53). In addition, EBV Mta and KSHV ORF57 also
bind to RNA to facilitate RNA export (54, 55). It is unique,
though, that RTA may bind to RNA specifically and modulate the
RNA synthesis. However, the nature of the RNA binding activity
and of the detailed mechanism for the regulation of MyD88 RNA
synthesis requires further investigation.
Recently there was a report that RTA degrades MyD88 through
the proteasome pathway (56), which apparently fits with the abil-
ity of RTA to function as an E3 ligase. This is apparently contra-
dictory to the results we report here. Under the conditions of our
studies, the proteasome pathway does not appear to be the pre-
dominant mechanism. First, the half-life of MyD88 protein was
not changed drastically in the presence of RTA (Fig. 3). Second,
proteasome inhibitors (lactacystin) could not restore MyD88 pro-
tein expression in the presence of RTA (Fig. 4E). However, we
could not eliminate the possibility that proteasome may play cer-
tain roles, as the His-145 residue in the putative E3 ligase domain
of the RTA failed to modulate MyD88 expression (Fig. 2) (17, 21).
We speculate that the different cell types, transfection conditions,
and gene dosages used in these two studies may collectively con-
tribute to the apparent discrepancies. In any case, RTA may mod-
ulate MyD88 with multiple mechanisms under different circum-
stances, including the proteasome pathway.
Because MyD88 is critically involved in IL-1 and TLR signal-
ing, the results here suggest another novel pathway by which
KSHV blocks host innate immunity as well as inflammation. Be-
cause IL-1 inhibits viral replication at least in endothelial cells, and
IL-1 is abundant in the microenvironment of the KS, the blockage
of the IL-1 signaling pathway (Fig. 7) may help KSHV to counter-
act inflammation-mediated damaging effects (28–31). In addi-
tion, TLR4 has been identified as an important antiviral molecule
against KSHV infection, and KSHV has developed a mechanism
for rapid suppression of TLR4 expression (33). TLR4 activation
would lead to activation of both TRIF and MyD88, which further
leads to the induction of immunity against the virus. Therefore,
this RTA-mediated degradation of MyD88 and TRIF may be used
by KSHV to escape TLR4-mediated innate immunity against
KSHV (56). Finally, as the reduction of MyD88 was observed in
KSHV-infected cells under physiological concentrations in native
environments (Fig. 1 and 4), this phenomenon might naturally
occur in individuals who have KSHV infection in vivo.
MyD88 is a multifunctional adaptor protein, mediating activa-
tion of several transcription factors, including NF-B, a key me-
diator for proinflammatory cytokines (for a review, see reference
25). Additionally, TLR may induce apoptosis, and MyD88 is re-
quired in certain situations (24). The reduction of MyD88 may
apparently alleviate the potential apoptosis process. It is tempting
to speculate that RTA-mediated MyD88 regulation may not be
limited to the blockage of host inflammation and immunity but
may also include other cellular activities for the benefits of KSHV
replication in vivo.
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